Skip to content

Hearing Aids as a Treatment for Tinnitus in Mild Hearing Loss.

Hearing Aids as a Treatment for Tinnitus in Mild Hearing Loss.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21763
Enrollment
40
Registered
2009-09-10
Start date
2010-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tinnitus mild hearing loss hearing aid oorsuizen hoortoestellen mild gehoorverlies

Interventions

A hearing aid is bilaterally fitted. The hearing aid has mild amplification and an open ear-canal fitting.

Sponsors

University Medical Center Groningen (UMCG), dep. of Otorhinolaryngology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults (>18years); 2. Tinnitus complaint; 3. Symmetric hearing loss (threshold >= 20dB on 2 and/or 4kHz); 4. A pure tone average threshold = PTA 1-2-4kHz <35dB.

Exclusion criteria

Exclusion criteria: 1. An otological condition that needs intervention by an ENT surgeon; 2. A psychiatric condition that needs intervention by a psychiatrist; 3. A non cooperative patient.

Design outcomes

Secondary

MeasureTime frame
The effect of hearing aids will be evaluated on the ability to hear in patients with mild hearing loss.

Primary

MeasureTime frame
To evaluate the effect of a hearing aid for the treatment of tinnitus in patients with mild hearing loss and to evaluate the relation with four patient characteristics (see introduction): 1. Amount of hearing loss; 2. Tinnitus frequency; 3. Tinnitus handicap; 4. Psychological distress. Before, after 6 weeks of use and after 6 months of hearing aid use, the effect is evaluated by a free-field speech audiometry, tinnitus loudness matching and questionnaires to evaluate the tinnitus handicap and a distress.

Contacts

Public ContactK.M. Heijneman

Universitair Medisch Centrum Groningen, afd. Keel-,Neus-, Oorheelkunde Postbox 30.001

k.m.heijneman@kno.umcg.nl+31503618053

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)